BioServe adds next generation sequencing capabilities to its “sample to validated data” genomic services platform
Beltsville, MD., December 12, 2011: BioServe today announced an expanded relationship with Fox Chase Cancer Center, who is a foundation member of the BioServe Network of leading sample biorepositories. In this expanded relationship, BioServe will be working with Fox Chase to provide clients with next generation sequencing capabilities. Fox Chase has outfitted a new internal laboratory utilizing next-generation sequencing and analysis platforms and novel biological information technology systems for advanced analysis of genomic data.
“We are excited offer our customers next generation sequencing through Fox Chase. BioServe is uniquely positioned to be a single partner that can provide high quality human tissue samples and generate validated data from those samples to accelerate discovery,” said Rama Modali, President, BioServe.
“Accessing our industrial scale BioRepository of individual patient DNA, RNA and serum, researchers can leverage our genomic services to interrogate the entire biological spectrum – genome, transcriptome and metabolome.
In particular, BioServe’s BioRepository contains high-quality, high-yield DNA ready for next generation sequencing analysis, for example:
- Cardiovascular disease – 27,000 patients
- Diabetes – 12,000 patients
- Arthritis – 7,500 patients
- Asthma – 3,000 patients
- Normal, healthy controls – 12,000 donors
In addition, BioServe has high quality samples ready for cancer genome analysis:
- Tumor DNA from 3,000 patients
- Matched pairs samples (tumor + normal adjacent tissue) from 300 donors in breast and colon, 160 donors in lung cancer, 200 donors in gastric cancer, 60 uterine cancer
“Life science research firms can now obtain high quality human samples from our BioRepository and sample Network, as well as use BioServe for sample preparation, extraction, genotyping and now next generation sequencing. There are few service providers who can now match our breadth and quality of genomic service offerings,” Modali added.
“Fox Chase is focused on using genomic sequencing to help develop personalized medicine strategies for cancer care. To this end, we have outfitted our capabilities with the most advanced sequencing and analysis capabilities,” said Dr. Kurt Schwinghammer,